| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.08.120 |
| P698 | PubMed publication ID | 15514377 |
| P50 | author | Jörg Debatin | Q1715280 |
| Andreas Bockisch | Q27342068 | ||
| Gerald Antoch | Q110980843 | ||
| P2093 | author name string | Hilmar Kuehl | |
| Thomas Beyer | |||
| Lutz S Freudenberg | |||
| Stefan P Mueller | |||
| Gerlinde Dahmen | |||
| Nina Saoudi | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorine | Q650 |
| glucose | Q37525 | ||
| computed tomography | Q32566 | ||
| positron emission tomography | Q208376 | ||
| Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography | Q130273251 | ||
| P304 | page(s) | 4357-4368 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. | |
| P478 | volume | 22 |
| Q37119144 | 18F-FDG PET/CT evaluation of patients with ovarian carcinoma |
| Q46101352 | 18F-FDG PET/CT findings of sinonasal inverted papilloma with or without coexistent malignancy: comparison with MR imaging findings in eight patients |
| Q43116161 | 18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results |
| Q36628242 | 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma |
| Q24626790 | A new standard of care for the management of peritoneal surface malignancy |
| Q43167555 | Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center |
| Q35763359 | Accuracy of [18F]FDG PET/MRI for the Detection of Liver Metastases |
| Q34662750 | Advances in bladder cancer imaging |
| Q33367167 | An integrated MR/PET system: prospective applications |
| Q42176053 | Awareness and current knowledge of breast cancer. |
| Q33704400 | Clinical Significance of Diffuse (18)F-FDG Uptake in Residual Thyroid Gland after Unilateral Thyroid Lobectomy |
| Q37139413 | Clinical biomarkers of angiogenesis inhibition |
| Q53477419 | Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. |
| Q92617526 | Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma |
| Q37773735 | Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence. |
| Q43207600 | Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma |
| Q39889585 | Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? |
| Q37165522 | Combined 18F-FDG PET/CT Imaging for the Initial Evaluation of Glottic Cancer |
| Q37357107 | Combined PET/MRI: a new dimension in whole-body oncology imaging? |
| Q52888946 | Combined positron emission tomography/computed tomography (PET/CT) for imaging of orbital tumours and tumours extending into the orbit. |
| Q35642749 | Combined unsupervised-supervised classification of multiparametric PET/MRI data: application to prostate cancer |
| Q36924872 | Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma |
| Q35609723 | Comparison of PET with PET/CT in detecting peritoneal carcinomatosis: a meta-analysis |
| Q33578194 | Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer |
| Q36325275 | Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: initial results |
| Q46443845 | Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. |
| Q84757528 | Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT |
| Q83964083 | Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer |
| Q46416802 | Diagnostic value of PET/CT for the staging and restaging of pediatric tumors |
| Q38391343 | Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis |
| Q53422544 | Discovering Macrophage Functions Using In Vivo Optical Imaging Techniques. |
| Q37477631 | Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging |
| Q85825578 | Efficacy of 18F-fluorodeoxyglucose positron emission tomography/CT imaging for extracapsular spread of laryngeal squamous cell carcinoma |
| Q30829156 | Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions |
| Q37807623 | Extended staging of oesophageal cancer using FDG-PET – A critical appraisal |
| Q64265276 | F-FDG PET/CT performed immediately after percutaneous ablation to evaluate outcomes of the procedure: preliminary results |
| Q36485366 | FDG positron emission tomography/computed tomography studies of Wilms' tumor |
| Q53479198 | FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. |
| Q39271078 | FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies |
| Q33847261 | Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients |
| Q38174895 | Fluorodeoxyglucose uptake in absence of CT abnormality on PET-CT: What is it? |
| Q39776437 | Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers |
| Q57712651 | Funktionelle und molekulare Bildgebung bei Brusttumoren |
| Q46025661 | Gastrointestinal 18F-FDG accumulation on PET without a corresponding CT abnormality is not an early indicator of cancer development. |
| Q37713095 | Heterogeneity in Cancer Metabolism: New Concepts in an Old Field |
| Q37658819 | Imaging as a surveillance tool in rectal cancer |
| Q43597462 | Imaging of mandible invasion by oral squamous cell carcinoma using computed tomography, cone-beam computed tomography and bone scintigraphy with SPECT. |
| Q45075447 | Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer |
| Q41614765 | Improved short tau inversion recovery (iSTIR) for increased tumor conspicuity in the abdomen |
| Q39841564 | In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography |
| Q34544791 | Incidental Thyroid Carcinoma by FDG-PET/CT: A Study of Clinicopathological Characteristics |
| Q46078840 | Incidental head and neck (18)F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development? |
| Q37320517 | Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer |
| Q81527062 | Initial clinical results for breath-hold CT-based processing of respiratory-gated PET acquisitions |
| Q51934944 | Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. |
| Q38551826 | Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results |
| Q37682460 | Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area? |
| Q43517536 | Is there a need for positron emission tomography imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx? |
| Q33627586 | Is there any role of positron emission tomography computed tomography for predicting resectability of gallbladder cancer? |
| Q37951788 | Lymphadenectomy in penile cancer |
| Q46185650 | Meta-analysis of diagnosis of liver metastatic cancers: comparison of (18) FDG PET-CT and gadolinium-enhanced MRI. |
| Q36355220 | Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. |
| Q38975266 | Minimal Invasive Management of Lymph Nodes |
| Q35016225 | Molecular Imaging in Breast Cancer - Potential Future Aspects |
| Q30433423 | Molecular imaging agents: impact on diagnosis and therapeutics in oncology |
| Q57712624 | Molekulare Brustbildgebung |
| Q37357117 | Multimodality imaging: an update on PET/CT technology |
| Q36981044 | Multiple Scalp Lesions in a Patient with Keratitis, Ichthyosis and Deafness Syndrome Mimicking Metastatic Squamous Cell Carcinoma on 18F-FDG PET/CT |
| Q35941636 | Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis |
| Q38268168 | Nuclear medicine in urological cancers: what is new? |
| Q35673572 | Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment |
| Q37988785 | Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer |
| Q53466973 | PET-CT in oncology. |
| Q46111693 | PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences |
| Q43208632 | PET/CT colonography: a novel non-invasive technique for assessment of extent and activity of ulcerative colitis |
| Q53251672 | PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. |
| Q37767627 | PET/CT in primary musculoskeletal tumours: a step forward |
| Q37115489 | PET/MRI hybrid imaging: devices and initial results |
| Q36605026 | PET/MRI: Technical Challenges and Recent Advances |
| Q30559454 | PET/MRI: challenges, solutions and perspectives |
| Q35073488 | Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians |
| Q46049423 | Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. |
| Q46640139 | Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. |
| Q43233300 | Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. |
| Q45332405 | Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. |
| Q38238226 | Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities |
| Q53491574 | Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. |
| Q53086997 | Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients. |
| Q34768592 | Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? |
| Q46532690 | Postoperative FDG-PET/CT staging in GIST: Is there a benefit following R0 resection? |
| Q43001893 | Postoperative distal ureteric and bladder cuff recurrence in a Grade I renal transitional cell carcinoma diagnosed and restaged by fluorodeoxyglucose positron emission tomography-computed tomography |
| Q37385860 | Pre-clinical PET/MR: technological advances and new perspectives in biomedical research |
| Q43049537 | Predictive value of 18(F)-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer |
| Q34072096 | Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy |
| Q44818137 | Preoperative 18F-FDG PET/CT and high-risk HPV in patients with oropharyngeal squamous cell carcinoma |
| Q53250271 | Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. |
| Q38412275 | Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma |
| Q53003832 | Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. |
| Q37413672 | Prognostic value of metabolic tumor burden in lung cancer |
| Q92642186 | Quality Improvement Initiatives to Assess and Improve PET/CT Injection Infiltration Rates at Multiple Centers |
| Q53014495 | Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary? |
| Q38925887 | Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer |
| Q42708105 | Role of Integrated PET/CT Fusion in Lung Carcinoma. |
| Q92899463 | Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval |
| Q39883690 | Sensitivity of 2-[18F]fluoro-2-deoxyglucose positron emission tomography for advanced colorectal neoplasms: a large-scale analysis of 7505 asymptomatic screening individuals |
| Q30836539 | Simultaneous PET/MRI: Impact on cancer management-A comprehensive review of cases |
| Q53398926 | Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. |
| Q28070239 | The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations |
| Q46818567 | The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings |
| Q51853332 | The early use of PET-CT alters the management of patients with esophageal cancer. |
| Q46698912 | The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. |
| Q43410969 | The impact of coaxial core biopsy guided by FDG PET/CT in oncological patients. |
| Q53545405 | The role of FDG-PET/CT in the detection of recurrent colorectal cancer. |
| Q36712972 | The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers |
| Q45038434 | The role of PET/CT imaging in penile cancer |
| Q37210598 | The role of positron emission tomography in the management of non-small cell lung cancer. |
| Q53454869 | Transbronchial needle aspiration accurately diagnoses subcentimetre mediastinal and hilar lymph nodes detected by integrated positron emission tomography and computed tomography. |
| Q46921870 | Tumor staging using whole-body high-resolution 16-channel PET-CT: does additional low-dose chest CT in inspiration improve the detection of solitary pulmonary nodules? |
| Q42564768 | Use of PET/CT scanning in cancer patients: technical and practical considerations |
| Q53511970 | Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. |
| Q45042464 | Utility of 18F-FDG PET/CT in supracricoid partial laryngectomy |
| Q38018970 | Virtual 18F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients: present and future applications |
| Q53022103 | Who should undergo a colonoscopy among patients with incidental colon uptake on PET-CT? |
| Q42871039 | Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma |
| Q46991115 | Whole-body MRI and PET-CT in the management of cancer patients |
| Q49990418 | Whole-body MRI for metastatic cancer detection using T2 -weighted imaging with fat and fluid suppression |
| Q44896473 | Whole-body PET/CT imaging: combining software- and hardware-based co-registration. |
| Q83781983 | Whole-body hybrid PET/MRI: ready for clinical use? |
| Q36842459 | Whole-body imaging of the musculoskeletal system: the value of MR imaging |
| Q92582237 | Whole-body magnetic resonance for staging and response assessment of lymphoma in a pregnant woman treated with antenatal chemotherapy |
| Q39128819 | [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results |
| Q79564128 | [MSCT for staging and response evaluation of esophageal cancer] |
| Q53212857 | [Modern CT and PET/CT imaging of the liver]. |
| Q53098254 | [Multiparametric imaging with simultaneous MR/PET. Methodological aspects and possible clinical applications]. |
| Q52988169 | [Multiparametric imaging with simultaneous MRI/PET: Methodological aspects and possible clinical applications]. |
| Q53584110 | [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers]. |
| Q36212460 | [¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case |
Search more.